8-KLeadership ChangesExhibits & Filings

DEXCOM INC 8-K Report, Executive Changes (May 13, 2025)

Filed May 13, 2025For Securities:DXCM

Summary

DexCom, Inc. (DXCM) has announced a significant leadership change with the promotion of Jacob S. Leach to President and Chief Operating Officer, effective immediately. This appointment places Mr. Leach directly under CEO Kevin Sayer and signifies a strengthening of the operational leadership team. Investors should note that Mr. Leach's compensation has been adjusted to reflect his new role, including a base salary of $800,000 and eligibility for a performance-based annual cash bonus targeted at 100% of his base salary. This promotion is a key development for DexCom as it continues to execute its growth strategy in the diabetes technology market. The elevated role for Mr. Leach, who has been with the company, suggests confidence in his ability to drive operational execution and strategic initiatives. The associated compensation structure is designed to incentivize strong performance and align executive interests with those of shareholders.

Key Highlights

  • 1Jacob S. Leach promoted to President and Chief Operating Officer, effective immediately.
  • 2Mr. Leach will report directly to CEO Kevin Sayer.
  • 3Annual base salary for Mr. Leach increased to $800,000.
  • 4Mr. Leach is eligible for an annual cash performance bonus with a target of 100% of base salary.
  • 5Mr. Leach remains eligible for employee benefit plans and the company's Severance & Change in Control Plan.
  • 6Biographical and related party transaction information for Mr. Leach is incorporated by reference from the March 27, 2025 proxy statement.
  • 7The announcement was made via a press release dated May 13, 2025, attached as Exhibit 99.1.

Frequently Asked Questions

This promotion signifies an elevation of operational leadership within DexCom. As President and COO, Mr. Leach will play a key role in executing the company's strategy and driving day-to-day operations, reporting directly to the CEO.

Mr. Leach's annual base salary has been increased to $800,000. He is also eligible for an annual cash performance bonus with a target of 100% of his base salary, with the actual payout determined by the compensation committee.

No, Mr. Leach remains eligible to participate in the company's standard employee benefit plans and is also covered under DexCom's Amended and Restated Severance & Change in Control Plan.

Detailed biographical information, family relationships, and any related party transactions for Mr. Leach are incorporated by reference from DexCom's definitive proxy statement filed on March 27, 2025.